



CODEN [USA]: IAJ PBB

ISSN : 2349-7750

**INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES**

SJIF Impact Factor: 7.187

<https://doi.org/10.5281/zenodo.23279147>Available online at: <http://www.iajps.com>

Review Article

**CHALLENGES IN DESIGNING ANDA FOR PARENTERAL
PRODUCTS****Boorugu Meghana*, Ch. Sunitha**Department Of Regulatory Affairs, Princeton College Of Pharmacy, Pocharam, Hyderabad,
Telangana 500088.**Abstract:**

Quality by Design (QbD) is a systematic approach that focuses on understanding and controlling product quality through the integration of scientific principles, risk management, and regulatory requirements. This abstract provides a comprehensive overview of the application of QbD principles in the development of parenteral drug formulations, which are administered via injections, infusions, or implants. Employing Quality by Design (QbD) during the development of parenteral drug formulations yields substantial advantages as it facilitates a thorough comprehension of the interplay amongst formulation variables, process parameters, and critical quality attributes (CQAs). By employing a proactive and science-based approach, manufacturers can optimize product quality, reduce batch failures, and enhance patient safety and efficacy. The QbD approach in parenteral drug formulations involves several key elements. The first step is to identify and define the Critical Quality Attributes (CQAs) that are crucial to ensure the safety and effectiveness of the drug product. These attributes include parameters such as potency, purity, stability, and drug release profiles. Secondly, QbD encourages the establishment of a design space, which defines the acceptable ranges of formulation and process parameters that ensure product quality within the desired CQA specifications. Furthermore, QbD promotes a lifecycle approach, encompassing the entire product lifecycle from development to post-approval changes. This involves continuous process verification, ongoing monitoring of product performance, and the implementation of quality control strategies to ensure consistency and reliability. In conclusion, the application of QbD principles in parenteral drug formulations offers a robust and science-based approach to ensure product quality, safety, and efficacy. By leveraging these principles, manufacturers can optimize formulations, control critical parameters, and enhance process.

Corresponding author:**Boorugu Meghana,**Department of Regulatory Affairs, Princeton college of Pharmacy,
Pocharam, Hyderabad

Mobile:

Email Id: princeton.pharmacy@gmail.com

QR CODE



Please cite this article in press **Boorugu Meghana et al., Challenges In Designing Anda For Parenteral Product., Indo Am. J. P. Sci, 2026; 13(10).**

INTRODUCTION:

Its department has the responsibility of acquiring FDA permission for new pharmaceutical items and keeping it so the product could be sold indefinitely. The project plan is the link between the regulatory agency and the project team, ensuring that the regulatory authority's requirements are appropriately predicted. RA is tasked for keeping up with important new laws, rules, and regulations. As a result, regulators expect corporations to interpret rules and recommendations. Staff from the RA help project managers understand and apply the rules. Concerns about guidelines, clinical research, and formulation formulation must be aired with authorities early in the process. Most companies prioritise new initiatives based on a TPP. The RA professional's work determines what data should be on the product's "label." RA is also a member of the project team can help create the programme. Regulations are meticulously reviewed before being handed to the RA department for review. This team also drafts core prescription information used for global approval and marketing. Filings for new products and modifications to existing items are included. This obligation occupies a large chunk of the RA department's job. The RA's role is to provide input on proposed or debated legislation.² This is a proactive action. In the ICH context, there is more chance to influence early in the process. Regulators ensure the safety and efficacy of healthcare products globally.

Regulatory professionals include individuals in charge of ensuring regulatory compliance, writing submissions, clinical affairs, and quality assurance. The regulatory professional of an export company must first obtain product registration and clearance from the country's health agency, such as the FDA in the US or the EMA in the EU.

•Food and cosmetics are among the many products regulated by regulatory specialists.

•The following are examples of Parental:

•veterinary goods, in vitro diagnostics, biologics & biotechnology, nutritional products, cosmetics

•Premarket approvals, manufacturing, labelling, and advertising, as well as postmarket surveillance, are all part of the regulatory professional's job description and responsibilities.

Role of regulatory Authority and Company

A regulatory agency is a government-created enforcement organisation tasked with monitoring and implementing workplace health and safety regulations. Establishing and enforcing safety standards is the responsibility of the regulatory authority.

Don't overstep your authority^{2,3}

In order to benefit from third-party benefits, one must refrain from accepting them in order to promote the company's performance, exercise independent judgement, and use reasonable care, skill, and diligence.




Figure1: Role of Regulatory Affairs

Several tragedies in the 1950s, such as the sulfanilamide elixir, the vaccination disaster, and the thalidomide tragedy, led to a significant increase in the number of laws governing drug quality, safety, and efficacy in the United States.^{4,5} More stringent requirements for things like marketing authorizations and GMPs have resulted as a result of this (GMPs). Let's take a look at what transpired in the United States, Europe, and India over the past few days.

USA⁴⁻⁸

The first large-scale production of glycerine occurred between 1818 and 1840, when chemical manufacturing factories began to spring up in the early 18th century. Pharmacists and doctors, on the other hand, synthesised medicines in pharmacy laboratories. In response to the vaccination disaster, the Biologics Control Act of 1902 banned the production of all but the most basic of narcotics, such as opium. Biological items, such as serum, vaccine, toxin, and viruses, were to be licenced and labelled with the manufacturer's name, address, licence number, product identity, and expiration date (Figure 2). From the Import Medications Act of 1848 to the Biologics Control Act of 1902, the federal

government took steps to prevent food, drugs, medicines, and liquors from being tainted or mislabeled. This statute made it illegal to ship tainted food and Parental across state lines. Preservatives such as formaldehyde, copper and borax were prohibited from being used in food and medications under this rule. The 1906 Food and Drugs Act is better known as the Wiley Act, after Dr. Harvey W. Wiley, who coined the name for the law. Alcohol, cocaine, heroin, morphine, and opium were among the substances that had to be labelled under this rule.⁶ This was the first comprehensive national food and drug safety law (Figure 2). As a result of the Federal Food and Drugs Act of 1906, the Food and Drug Administration (FDA) was eventually established (FDA). In 1927, the Bureau of Chemistry was reformed into the Bureau of Chemistry and Soils and Food, Drug, and Insecticide Administration, which was originally employed to control food safety. After a reorganisation, the present Food and Drug Administration (FDA) was established in 1930. FDA commemorates 1906 as the year it was founded because that was the year it was founded at its very roots.




Figure 2: Evaluation of Vaccine Industry

The fundamental goal of European healthcare regulations is to keep hazardous items off the market. Only a few other factors contributed

to the highly regulated and technologically advanced pharmaceutical sector. Then came postwar health insurance. As the cost of Parental

is shifted from individuals to commercial and governmental health insurance systems, pricing is becoming more transparent. CJD cases began to rise in the UK in the early 1990s. Humans can get bovine spongiform encephalopathy (BSE), also known as "mad cow disease." This illness was suspected to be caused by consuming BSE-infected beef. Based on this incident, legislation relevant to BSE and TSE free use of materials has been implemented.

India 8,9,10

The Poisons Act 1919 was passed to control cheap drugs. This statute prohibits the sale or possession of poisons. Poisons must be stored safely, labelled and packaged properly, sold in maximum quantities, and examined annually. Dangerous Drugs Act 1930 replaced the Poisons Act. This law regulates opium plant growth, production, ownership, import, export, transshipment, and sale. It repealed the Dangerous Drug Act of 1930 and the Opium Act of 1878. This era saw the enactment of the following laws:

The Drug & Cosmetic Act of 1940 regulates pharmaceutical import, manufacture, distribution, and sale. There are no exceptions to this law. The Drugs and Cosmetics Act regulates the manufacture of Ayurvedic drugs for sale, not consumption, usage, or possession.

The Pharmacy Act of 1948, last revised in 1986, governs the profession in India.

b) 1960-1970: Global businesses dominated the market, with few Indian producers. India's pharmaceutical industry was just taking off. Lack of patent protection reduced emphasis on pure R&D. Prices were high and supply were low due to the market's reliance on imports.

b) 1970-1980: The government took over drug regulation and issued few laws and rules.

The Indian Patent Act of 1970 established the country's patent system. Based on this, only Drug substance manufacturing procedure and method could be patentable. This act prohibited product patents. It came into force on April 20, 1972. This new law replaced the 1911 Indian Patents and Designs Act and took effect immediately.

The Drug Prices Control Order (DPCO) was designed to keep drug costs low. Local businesses have begun using reverse engineering to make things and Parental since the Indian

Patent Act 1970 authorised product patents. The lower cost of these new treatments made several cheaper and more easily available alternatives to the high-priced imported new Parental. This increased exports to countries including Russia, Africa, China, and South America. 2) Non-patent export of bulk drugs.

From 1980 to 1990, industry invested in developing API techniques and manufacturing facilities. The government has also aided exports. The Narcotic Drugs and Psychotropic Chemicals Act of 1985 regulates narcotic drugs and substances.

Between 1990 and 2000, the local pharmaceutical market grew substantially, as did globalisation. Businesses have begun their own study. After joining the Paris Cooperation Treaty in 1999, India adopted product patents on January 1, 2005. (PCT). f) 2000-2010: The period of Innovation and Research.

During these years, innovative research, patenting of pharmaceutical formula, procedure, indication, and enterprise mergers began.

• Patent Amendment Act 2005: This act provides that if a patent application is filed before January 1, 2005, the manufacturer can market the product after that date without infringing the patent, if the manufacturer has made significant investment in manufacturing the product before January 1, 2000.

ICH guidelines are divided into four categories

11-14

a.Q1-Q14 Quality Guideline A more flexible approach to pharmacological quality is based on Quality System Practice (GMP) risk management.

b.Concerns about carcinogenicity, genotoxicity, and reprotoxicity have been documented in the ICH safety guidelines (S1-S12). The most prevalent reason for drug discontinuation is QT interval prolongation.¹²

c.Efficacy E1-E20 Efficacy work is involved with the design, conduct, safety, and reporting of clinical research. It also includes new drugs developed by biotechnological methods and more focused therapies using pharmacogenetics/genomics.

d.Guideline M1-M13 Those are the topics that cross over into Quality, Safety, and Efficacy. That is, the ICH medical language, the Common Technical Document, and the creation of Electronic Standards for Regulatory Information Transfer (ESTRI) (ESTRI).



Figure: 3 Classification of ICH activities into Four Categories

Drug Approval Process ^{16,17}

A drug's FDA approval means that the drug's advantages outweigh its known and potential dangers for the targeted demographic. The drug approval process follows a framework that includes:

- Reviewers examine the risks and benefits of the drug against the current treatment landscape and the target condition. For example, while the hazards of a non-life-threatening sickness are undesirable, they may be tolerable for a life-threatening condition
- Clinical data benefit and risk assessment: FDA reviewers assess clinical data benefit and risk, taking into account any uncertainties that may arise from defective or incomplete data. To ensure that a first trial's results are not due to chance or prejudice, the FDA normally requires two properly conducted clinical trials. In some cases, especially when the disease is rare and multiple studies are not feasible, one clinical trial's findings may be sufficient. The evidence that the drug will help the target group should outweigh the hazards. Any drug has some level of danger. An FDA-approved drug label discusses the benefits and risks of a drug, as well as how to detect and manage risks.

Hazard mitigation requires extra effort at times. As a result, a drug maker may need to develop a Risk Management and Mitigation Strategy (REMS) (REMS).

However, the FDA's risk-benefit studies and findings are not always clear-cut. The FDA review committee may come to different conclusions than the medicine developer after analysing the same data. As a science-led agency, FDA uses the best available research and technology to make judgments.

Quicker Authorization

In some cases, a new drug's approval is rushed. Accelerated Approval is available for new medications that cure serious or life-threatening illnesses and outperform conventional therapies. This strategy enables for the approval of drugs that show a therapeutic benefit on a "surrogate endpoint" that occurs earlier but is not as robust as the regular endpoint used for approval. This approval approach is especially useful when a medicine's effects must be investigated over a longer period of time. Post-market clinical trials are required to validate and describe the drug's benefit.




Figure 4: Drug Approval Process

Since its beginning in 1992, the Rapid Approval process has authorised numerous life-saving therapies that have significantly influenced disease progression. Examples include various antiretroviral drugs that were quickly approved and later changed the therapeutic paradigm. This approach has also helped bring a number of cancer-fighting drugs to market.

Guidance For New Drug Application^{19,20,21,22}

The EPA's guideline materials reflect current thinking on a topic. These resources were prepared for FDA review staff and can be used by applicants and sponsors for application processing, content, evaluation/approval, and design, development, manufacturing, and testing of regulated products. They also set policies and procedures for inspection and enforcement of the Agency's regulations. Because they are neither regulations nor laws, they cannot be enforced administratively or judicially. Alternative strategies are legal if they meet the necessary statutory and regulatory standards.

The New Drug Application has supervised and controlled new medications in the US for decades (NDA). Before any new medicine may be sold in the US, it must be approved by

the FDA. The NDA application is how pharmaceutical companies ask the FDA to approve a new drug for sale in the US. The NDA includes data from animal and human clinical trials for an Investigational New Drug (IND).²²

- Whether the medicine is safe and effective for the suggested use(s) and whether the benefits of the treatment outweigh the risks. Concerns about the drug's intended labelling (package insert).

A drug's identity, strength, quality, and purity must be maintained by manufacturing processes and quality controls.

An NDA is expected to include all aspects of a drug's life cycle, from development and testing to human and animal studies to packaging and distribution.

India's drug policy is overseen by both the central and state governments. It is the responsibility of CDSCO to approve new drugs, conduct clinical trials in the country, set standards for drugs, monitor the quality of imported drugs, coordinate the activities of state drug control organisations, and provide expert advice to ensure uniformity in the enforcement of the Drugs and Cosmetics Act. This essay will describe the New Drug Approval Process in India.

Next Page Export Data Import Data Reset Form	
DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION APPLICATION TO MARKET A NEW DRUG, BIOLOGIC, OR AN ANTIBIOTIC DRUG FOR HUMAN USE (Title 21, Code of Federal Regulations, Parts 314 & 301)	
Presubmission CDRH No. 0079-0038 (Updated: April 2018) See CDRH Website for page 2.	
FOR FDA USE ONLY APPLICATION NUMBER: _____	
APPLICANT INFORMATION	
NAME OF APPLICANT: _____	DATE OF SUBMISSION: _____
TELEPHONE NO. (Include Area Code): _____	FACSIMILE (FAX) Number (Include Area Code): _____
APPLICANT ADDRESS (Number, Street, City, State, ZIP Code or Mail Code, and U.S. Source number if previously issued): _____	AUTHORIZED U.S. AGENT NAME & ADDRESS (Number, Street, City, State, ZIP Code, Telephone & FAX number if APPLICABLE): _____
PRODUCT DESCRIPTION	
NEW DRUG OR ANTIDOTE APPLICATION NUMBER, OR BIOLOGIC (if first application number (if previously issued): _____ EXTENDED INDICATION (E.I.) (If not applicable, leave blank): _____ PROPRIETARY NAME (Trade Name) (if any): _____	
COMMON (GENERIC) PRODUCT NAME (if any): _____	CODE NAME (if any): _____
BIOLOGIC FORM: _____	STRENGTH: _____
ROUTE OF ADMINISTRATION: _____	
PREVIOUS (INDICATIONS) FOR USE: _____	
APPLICATION DESCRIPTION	
APPLICATION TYPE (check one) ☐ NEW DRUG APPLICATION (NDA, 21 CFR 314.50) ☐ ABANDONED NEW DRUG APPLICATION (ANDA, 21 CFR 314.54) ☐ INDUSTRY USE ONLY (INDUSTRY USE ONLY APPLICATION (IUA, 21 CFR 314.55))	
IF ANANDA, IDENTIFY THE APPROPRIATE TYPE: ☐ NOS 301 ☐ NOS 302	
IF ANANDA, OR ANANDA, IDENTIFY THE SUBMISSIONS LISTED UNDER PARAGRAPH THAT IS THE BASIS FOR THE SUBMISSION: _____	
Name of Drug: _____	Number of Approved Applications: _____
TYPE OF SUBMISSION (check one) ☐ ORIGINAL APPLICATION ☐ AMENDMENT TO ORIGINAL APPLICATION ☐ REVISION ☐ SUPPLEMENT ☐ SUPPLEMENTAL INDICATION ☐ SUPPLEMENTAL INDICATION ☐ SUPPLEMENTAL INDICATION ☐ SUPPLEMENTAL INDICATION	
IF A SUBMISSION OF PARTIAL APPLICATION, PROVIDE LETTER DATE OF AGREEMENT TO PARTIAL SUBMISSION: _____	
IF A SUPPLEMENT, IDENTIFY THE APPROPRIATE CATEGORY: ☐ LDR ☐ LDR-18 ☐ Prior Approval (PA)	
REASON FOR SUBMISSION: _____	
PROPOSED MARKETING STATUS (check one) ☐ PRESCRIPTION PRODUCT (PR) ☐ OVER THE COUNTER PRODUCT (OTC)	
NUMBER OF VOLUMES SUBMITTED: _____ THIS APPLICATION IS: ☐ PAPER ☐ PAPER AND ELECTRONIC ☐ ELECTRONIC	
ESTABLISHMENT INFORMATION (Full establishment information should be provided in the body of the application.) Provide location of all manufacturing, packaging and control sites for drug, biological and drug product combination (where applicable). Include name, address, contact, telephone number, registration (if any), GPO, DVP, system, and manufacturing steps, unit type of coding (e.g., Pack (single-unit), multi-unit), and type of coding (e.g., Pack (single-unit), multi-unit). Provide contact information for the site(s) to be inspected (if any, when it is not on file).	
Cross References (for related License Applications, NDAs, NDAs, PMAs, STXs, EAs, SPPs, and DRPs referenced in the current application): _____	

Figure 5: Application form for newdrug Process in Market

On March 19, 2019, India issued G.S.R. 227 (E) which covers all new Parenteral, experimental innovative medications for human use, 24 clinical trials, bioequivalence studies, bioavailability research, and Ethics Committee. These rules

are called the New Medicines and Clinical Trial Rules, 2019.

Examining the Indian legal definitions of "Drug" and "Novel Drug" can help us better understand the clearance period for new Parenteral.




Figure: 6 drug License Online Process

The Drugs act Act of 1940, section 3(a) defines this medication as:²³⁻²⁵

- 1.All drugs for internal or external use in humans or animals, including formulations used to the skin to repel insects like mosquitoes;
- 2.The Central Government may prescribe items (other than food) to exterminate rodents or insects that bring disease to humans or animals. These are ii substances.
- 3.empty gelatin capsules, which are designed to be used in medication;
- 4.equipment designed for internal or external use in diagnosing, treating, mitigating or preventing sickness or disorder in humans or animals, as determined by the Central Government in consultation with the Board.

Rule 2 (w) of the 2019 New Drugs and Clinical Trial Rules states:

- 1.One that has not been utilised in the country in any substantial way except as provided by law and rules made thereunder, and has not been approved by the Central Licensing Authority as safeand effective with respect to its claims.
- 2.A medicine's indication, method of administration, dosage, and dosage form must be approved by the Central Licensing Authority before it may be sold (ii).
- 3.Indication, route of administration, dosage, and dosage form are all proposed to be changed in a fixed dose combination of two or more medications authorised separately for specified claims and proposed to be combined for the first time.
- 4.This includes any medicine approved by the CLA in modified or sustained release form, or in a novel drug delivery technology.
- 5.living modified organism (LMO), monoclonal anti-body, stem cell derived product, gene therapy product or xenografts

6.Except for Parenteral listed in subclauses (iv) and (v), the Central Licensing Authority must consider new drugs for four years after they are licenced (v).

If the proposed drug substance or drug product falls under the New Drug definition, the firm must follow multiple regulatory procedures. Major elements affecting regulatory processes include:²⁶

- 1.The type of drug substance or medicinal product is a significant aspect in determining the approval process. Novel drugs are defined as those that are made from recombinant Deoxyribonucleic Acid (r-DNA), live modified organisms (LMO), monoclonal antibodies, stem cell derived products, gene therapy products or xenografts. As a result, any manufacturer wishing to market any of these drugs must conduct extensive non-clinical and clinical studies to demonstrate their safety and efficacy.
- 2.The type of formulation factors in influencing the approval process. Modified or sustained release medication forms or unique drug delivery technologies licenced by the Central Licensing Authority are always considered new drugs. So, before applying for a Marketing Authorization, every company must complete clinical trials and/or BA-BE investigations.
- 3.Drugs already approved in the US: The New Drugs and Clinical Trial Rules, 2019 provide that a drug is considered new for four years after the Central Licensing Authority approves it. During this time frame, a producer who desires to create a novel medicine for sale and distribution must also file a CT-21. This category will be studied closely as a model for new drug approval.
- 4.IND: INDs involve extensive research and testing, both clinical and non-clinical. Phase I clinical trials are followed by Phase II and Phase III. On the basis of these data, regulatory bodies

will decide whether or not to grant a Marketing Authorization.

5.Orphan Medications: Different standards can be relaxed for orphan drugs, but the Central Licensing Authority must approve. In such cases, a pre-submission meeting with CDSCO officials is advised to discuss and agree on the pathway.

6.New compounds, combinations, dosage forms, indications, dose, and delivery methods Before applying for a Marketing Authorization, a company must complete clinical trials and/or BA-BE investigations.

7.Notably, the dossier requirements include CMC, non-clinical, clinical, and administrative information.

8.As an example, let us imagine a drug that has been approved in India as a new drug but is still regarded a new drug because the Central Licensing Authority has not awarded it a four-year extension

Let's imagine a corporation wants to create a new drug that has just been approved by the Central Licensing Authority and hasn't been produced in four years. The path is as follows:

1.Apply for CT-11 or CT-14: A-B-E, or testing, analysing, and evaluating, is allowed under CT-11 and CT-14. CT-11/CT-14 The API approval status distinguishes CT-11 and CT-14. If API is obtained from a permitted source, permission is sought on CT-11; if obtained from an unapproved source, permission is sought on CT-14. The SUGAM portal is used to apply for CT-11 and CT-14.

2.To get Form 29 from the State Licensing Authority, the manufacturer must first obtain CT-11 or CT-14, if appropriate. Form 29 allows the creation of medications for research, testing, or analysis.

3.Making trial batches and collecting data: After receiving Form 29, a producer purchases API and other materials and makes trial batches. The Second Schedule of New Drugs and Clinical Trial Rules, 2019 requires all CMC data to be generated.

4.After that, a contract is formed with a Clinical Research Organization to conduct BA-BE studies for the company. Assembling and sending the BA-BE research protocol and its associated paperwork to the product manufacturer

5.CT-21 application: A corporation applies online to CDSCO. The Sixth Schedule of New Drugs and Clinical Trial Rules, 2019 requires all required information to be uploaded along with the application fee.

6.In case the regulatory body finds all the documentation sufficient, they may award CT-07 (permission to conduct BA-BE research on new medicine). Any

queries must be resolved prior to granting CT-07. CRO can start BA-BE study after receiving NOC.

7.Tested by the Indian Pharmacopoeia Commission in Ghaziabad. This is followed by a letter from the regulatory authorities requiring the producer get an analysis at the Indian Pharmacopoeia Commission in Ghaziabad. The manufacturer must then send the medicine sample for testing.

8.Upload additional data: After receiving the BA-BE research report and sample testing report, the manufacturer must upload them to the CDSCO portal

9.After data assessment, CT-23 is issued. So long as the regulatory authority is satisfied with the findings, it may grant CT-23 a licence to manufacture pharmaceutical formulations of novel drugs for sale or distribution.

10.SLA licence: After receiving CT-23, the drug maker must apply for a product permit on Form 25 or 28 from the State Licensing Authority.

Future Prospective Drug Regulatory

The pharma sector is shifting rapidly. The pharmaceutical sector is plagued by cost pressures and employee discontent. Recent trends show that obtaining new marketing authorizations, maintaining regulatory compliance, and assuring competitive personnel costs are becoming increasingly difficult. In addition, many pharmaceutical companies see the inability to handle local regulatory issues and monitor regulatory changes in important pharmaceutical markets as a substantial hindrance. Due to tighter market and trading conditions in the pharmaceutical business, more pharmaceutical and biotech decision-makers are considering outsourcing regulatory affairs services. This article explains why regulatory outsourcing is worthwhile, what duties are commonly considered for outsourcing, and what the future holds for RA outsourcing. The outsourcing of regulatory affairs services is already increasing proportionally, but a significant and sharper expansion of this set of services is anticipated in the future. This service's growth pattern parallels the growing need for clinical research outsourcing. Pharmaceutical companies would likely choose flexible collaboration and knowledge, which only regulatory affairs professionals can deliver. A completely standardised regional or worldwide level outsourcing will enable pharmaceutical businesses centralise regulatory affairs operations. The regulatory affairs service delivery model would be restructured to ensure worldwide coverage and uniform governance.

Owing to industrialization, financialization, demographic and natural resources dividends, liberal trade policies, and political and economic tie-ups, the BRICS (Brazil, Russian Federation, India, China, and South Africa) nations have registered their presence in international trade. It can figure out from their trade bills as imports and exports have witnessed an upward trend, especially in the preceding two decades ²⁷. To be specific, in 2014, the import bills of the BRICS nations reached to \$635 billion (US), which in 2005 accounted for \$286.2 billion (US) ²⁸. During the same period, exports from BRICS nations increased at an annual rate of 15.9%, whereas the average growth in exports across the world was reported as 8.8% per annum ²⁹. A closer examination of exports suggests that not only traditional products but also new and high technology products are now part of their export baskets. This is evident from the fact that high technology export-bills reached to \$775.14 billion (US) in 2015, which accounted for merely \$272 (US) in 2005 ²⁸. Besides the increase in international trade, multidimensional growth in internal markets enabled these nations to register consistently high GDP growth. As a result, per capita income of Brazil, Russia, India, China, and South Africa surged to \$11079.71 (US), \$11729.08 (US), \$2100.80 (US), \$7752.55 (US), \$7433.61 (US), respectively in 2018 ³⁰. In these nations, the average per capita income increased by two times from 1990 to 2018. However, during this period, per capita income in China and India increased by 11 and 4 times, respectively ³⁰. Furthermore, the growing exports of manufactured goods such as spacecraft, electrical equipment, telecommunication equipment, pharmaceutical products, etc., from BRICS nations' indicates that these nations have made significant efforts to strengthen their industrial infrastructure so that economic growth momentum can be maintained in the coming years ³¹.

Despite the above-said gains, BRICS nations appear to be struggling in dealing with health-related issues, racial discrimination, law and order, and unequal distribution of income ³². In recent years, the incessantly increasing environmental pollution has given another challenge to policymakers, which appears to be outcome of their inadequacy to develop renewable energy infrastructure and technological innovation. With growth in national income, it is expected that a country should start promoting research and technological innovation and budgetary allocation for such activities should be increased. However, despite witnessing a noticeable economic growth, expenditures on research endeavors in BRICS countries have remained well below than advanced countries. In comparison to the other four nations, budget allocation in China improved after 2003;

however, even China has to take giant steps to match the global research and development expenditures. The lackluster approach towards research and innovation might have caused energy deficiency and environmental pollution in BRICS nations because presently on both fronts these countries are struggling. The facts related to nitrous oxide emissions, carbon dioxide emissions, and energy consumption corroborates this notion. For example, in comparison to 1990, nitrous oxide emissions (thousand metric tons of CO₂ equivalent) increased by 32.60% in 2015–16.1 At the same time, the average CO₂ emissions increased to 6.49 (kg/oil equivalent) in 2015–16, whereas in 1990, carbon emissions accounted for 5.34 (kg/oil equivalent). During the same period, the average energy consumption in the BRICS nations increased from 2090 kg (oil equivalent/per person) to 2401.43 kg (oil equivalent/per person). In terms of income inequality, the situation in BRICS nations is not encouraging because, with increased domestic income, unequal distribution of income has grown, especially after the post-crisis period ³².

AIM AND OBJECTIVE:

Aim:

To explore and understand the scientific, technical, and regulatory challenges involved in the design and development of Abbreviated New Drug Applications (ANDA) for parenteral (injectable) products, with a focus on ensuring bioequivalence, sterility, and product quality.

OBJECTIVES:

1. **To identify** the critical requirements and regulatory expectations for submitting an ANDA for parenteral dosage forms to the USFDA and other regulatory authorities.
2. **To examine** the complexities associated with achieving pharmaceutical equivalence and bioequivalence for injectable products.
3. **To evaluate** challenges in formulation development, such as solubility, stability, container-closure compatibility, and excipient selection.
4. **To understand** the sterility assurance and process validation requirements critical for injectable drug products.
5. **To analyze** the analytical and characterization challenges, including particulate matter testing, pH, osmolarity, and preservative effectiveness.
6. **To study** the role of complex drug-device combinations (e.g., prefilled syringes, auto-injectors) and their implications on ANDA submission.

7. **To assess** the impact of scale-up, manufacturing site changes, and Quality by Design (QbD) approaches on ANDA approval success for parenterals.

CONCLUSION:

Designing an Abbreviated New Drug Application (ANDA) for parenteral products presents a unique set of challenges that go beyond those encountered with oral dosage forms. These challenges stem from the critical need to ensure sterility, safety, and therapeutic equivalence in highly sensitive formulations intended for direct administration into the body.

Parenteral formulations often involve complex manufacturing processes, stringent quality control requirements, and rigorous compliance with regulatory guidelines. Ensuring bioequivalence without conventional pharmacokinetic studies, especially in cases of locally acting injectables, adds further complexity. Additionally, formulation and container-closure compatibility, as well as stability concerns, require thorough scientific justification and robust data.

The need to maintain strict control over particulate matter, pH, osmolarity, and preservative effectiveness places a high demand on the analytical and process validation strategies. The integration of Quality by Design (QbD), advanced characterization methods, and risk-based approaches has become increasingly important in overcoming these hurdles.

In summary, while the ANDA pathway for parenteral products offers a cost-effective route to market for generic injectables, the pathway is technically demanding. Success requires deep scientific understanding, strategic planning, and adherence to evolving global regulatory expectations. Overcoming these challenges not only ensures regulatory approval but also contributes to the availability of safe, effective, and affordable parenteral medications for patients worldwide.

ACKNOWLEDGEMENT:

The Authors are thankful to Sura Labs, Dilshuknagar, Hyderabad for providing the necessary facilities for the research work.

REFERENCES:

1. Augustine, E. F., Adams, H. R., and Mink, J. W. (2013). Clinical Trials in Rare Disease: Challenges and Opportunities. *J. Child. Neurol.* 28 (9), 1142–1150. doi:10.1177/0883073813495959
2. Saha, P. (2020). EVOLUTION OF TOLBUTAMIDE IN THE TREATMENT OF DIABETES MELLITUS. *Diabetes*, 2, 10.
3. Basile, A. O., Yah, A., and Tatonetti, N. P. (2019). Artificial Intelligence for Drug Toxicity and Safety. *Trends Pharmacol. Sci.* 40 (9), 624–635. doi:10.1016/j.tips.2019.07.005
4. Nyarko, R. O., Kumar, R., Sharma, S., & Chourasia, A. (2022). Ayushmann Roy, and Purabi Saha. "Antibacterial Activity Of Herbal Plant-Tinospora Cordifolia And Catharthus Roseus.
5. Bate, A., and Hobbiger, S. F. (2021). Artificial Intelligence, Real-World Automation and the Safety of Medicines. *Drug Saf.* 44 (2), 125–132. doi:10.1007/s40264-020-01001-7
6. ZAIDI, S., MEHRA, R., & TYAGI, D. S. ROSHAN KUMAR ANUBHAV DUBEY. (2021). Effect of Kalahari Cactus Extract on Appetite, Body Weight And Lipid Profile In Cafeteria Diet Induced Obesity In Experimental Animal. *Annals of the Romanian Society for Cell Biology*, 25(6), 13976-13987.
7. Crisafulli, S., Ientile, V., L'Abbate, L., Fontana, A., Linguiti, C., Manna, S., et al. (2021). COVID-19 Patient Management in Outpatient Setting: A Population-Based Study from Southern Italy. *Jcm* 11 (1), 51. doi:10.3390/jcm11010051
8. Nyarko, R. O., Awuchi, C. G., Kumar, R., Boateng, E., Kahwa, I., Boateng, P. O., ... & Saha, P. (2022). Evaluation of Cafeteria Diet in Experimental Animal with Plant Extract of Calotropis procera for Obesity Parameter. *Journal for Research in Applied Sciences and Biotechnology*, 1(3), 107-113.
9. Digital Therapeutics Alliance (2021). Understanding DTx: A New Category of Medicine. Available at: <https://dtxalliance.org/understanding-dtx/>. (Accessed January 30, 2022).
10. Pandey, M., Singh, A., Agnihotri, N., Kumar, R., Saha, P., Pandey, R. P., & Kumar, A. (2022). Clinical Pharmacology & Therapeutic uses of Diuretic Agents: A Review. *Journal for Research in Applied Sciences and Biotechnology*, 1(3), 11-20.